Company / Cost of Revenue
Arcutis Biotherapeutics, Inc. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$36.7M
FY2025
5-year range
$0 / $36.7M
FY2021-FY2025
Trend
+91.8%
vs FY2024
Sector context
#58 of 85
Health Care
What the data says
At $37M, Arcutis Biotherapeutics, Inc.'s cost of revenue ranks #28 of 85 in the Health Care sector. Cost of Revenue has increased for 4 consecutive years, from $0 in FY2021 to $37M in FY2025.
Based on SEC 10-K filings.
$37M in FY2025 with a 3-year CAGR of +265.1%.
Increased from $5M to $37M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +265.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#28 of 85 in Health CareTop 32% of 85This company $36.7M Sector average $2.0B
▼
-98.1% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s cost of revenue has grown for 3 consecutive years.
- 3-year CAGR of +265.1%, indicating consistent growth.
- In FY2025, cost of revenue increased 91.8% year-over-year.
- Ranks #58 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.7M | +91.8% |
| FY2024 | $19.1M | +283.6% |
| FY2023 | $5.0M | +561.4% |
| FY2022 | $754.0K | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026